术中单剂美沙酮用于DIEP皮瓣乳房再造的加速康复外科路径
本研究回顾性纳入2020年10月至2021年3月的历史对照队列29例,并前瞻性纳入2021年4月至2022年1月实施以单次体重剂量术中美沙酮为核心的加速康复外科(ERAS)路径的54例患者,比较两组深下腹壁穿支皮瓣乳房再造的术后结局。结果显示ERAS组术后阿片类药物消耗、疼痛评分、心率和心动过速发生率均显著降低,住院时间无差异;作者认为美沙酮有潜力用于整形手术患者以减轻术后疼痛和阿片类药物使用。
要点
- ERAS路径以单次体重剂量术中美沙酮为核心,ERAS组54例与历史对照29例比较。
- ERAS组术后12小时、24小时及整个住院期间阿片类药物消耗显著减少。
- ERAS组术后24小时及整个住院期间疼痛评分显著降低,心动过速发生率显著降低。
核心结论
- 新建立的以单次术中剂量美沙酮为核心的ERAS路径的初步数据显示,可显著减少术后阿片类镇痛药使用、疼痛评分、心率和心动过速发生率。
- 这项先导研究显示美沙酮有潜力用于住院和门诊整形手术患者,以减轻术后疼痛、阿片类药物使用并提高整体舒适度和满意度。
研究设计与样本
- 回顾性历史对照队列(2020年10月至2021年3月,n=29)与前瞻性ERAS队列(2021年4月至2022年1月,n=54)比较。
- ERAS方案于2021年4月实施,核心为单次体重剂量的术中美沙酮。
- 采用单变量分析比较两组主要结局:住院时间、术后阿片类药物消耗、疼痛评分、心率和心动过速发生率。
主要发现
- ERAS组与非ERAS组住院时间无差异(P=0.68)。
- ERAS组术后12小时(P<0.001)、24小时(P<0.001)及整个住院期间(P=0.002)阿片类药物消耗显著少于非ERAS组。
- ERAS组术后24小时(P=0.021)及整个住院期间(P=0.0051)疼痛评分显著低于非ERAS组。
- ERAS组术后12小时(P=0.0014)、24小时(P<0.001)及整个住院期间(P<0.001)心率显著低于非ERAS组。
- ERAS组心动过速发生率显著低于非ERAS组(P=0.029)。
临床怎么用
- 作者认为美沙酮有潜力用于住院和门诊整形手术患者,以减少术后疼痛和阿片类药物使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inadequate postoperative pain relief places patients at risk for increased morbidity, including surgical complications and chronic postoperative pain. Previous studies have shown that just one dose of methadone can achieve better analgesia than multiple doses of short-acting opioids. This study aims to evaluate the effectiveness of our Enhanced Recovery After Surgery (ERAS) protocol for deep inferior epigastric perforator flap breast reconstruction centered around a single weight-based intraoperative dose of methadone. METHODS: The authors retrospectively reviewed patients from October 2020 to March 2021 to establish a historical control cohort (n = 29). The ERAS protocol was implemented in April 2021, and patients were prospectively enrolled in the ERAS cohort from April 2021 to January 2022 (n = 54). Primary outcomes compared between the ERAS and historical cohorts using univariate analysis were length of stay, postoperative opioid consumption, pain scores, heart rates, and incidence of tachycardia. RESULTS: There was no difference in the length of stay between our ERAS and non-ERAS cohorts (P = 0.68). Patients in the ERAS pathway had significantly less opioid consumption at 12 hours postoperatively (P < 0.001), 24 hours postoperatively (P < 0.001), and throughout the entire admission (P = 0.002). Pain scores were significantly lower in the ERAS cohort at 24 hours postoperatively (P = 0.021) and throughout admission (P = 0.0051). The ERAS cohort had significantly lower heart rates at 12 hours postoperatively (P = 0.0014), 24 hours postoperatively (P < 0.001), and throughout admission (P < 0.001). The incidence of tachycardia was also significantly lower in the ERAS cohort (P = 0.029). CONCLUSIONS: This preliminary data after newly instituting our ERAS protocol with a single dose of intraoperative methadone significantly reduced postoperative opioid analgesic usage, pain scores, heart rates, and incidence of tachycardia. This pilot study demonstrates that methadone has the potential to be used for patients undergoing plastic surgery procedures, both inpatient and ambulatory, to decrease postoperative pain, opioid use, and increase overall patient comfort and satisfaction.
引用
- Bernstein JL, Lu Wang M, Huang H, et al. Intraoperative Methadone: A New Enhanced Recovery After Surgery Pathway for Deep Inferior Epigastric Perforator Flap Breast Reconstruction. Ann Plast Surg. 2025. PMID: 40167055. doi:10.1097/SAP.0000000000003534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。